Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib, Blinatumomab, and Low-Intensity Chemotherapy in Ph+ ALL
NCT03147612Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2018
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib and blinatumomab in acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Complete molecular response at 84 days and Overall response at 6 years. Started Feb 2018; status: active, not recruiting.
02
Drugs
ponatinibblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT03147612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147612.